Physician profile
Philip A Schultz
NPI 1114900768
$308.03
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $16.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.88 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $52.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.63 | 2019 | |
| Merck Sharp & Dohme LLC | $36.56 | 2019 | |
| Cranial Technologies, INC | $34.56 | 2019 | |
| Kaleo, INC. | $33.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.53 | 2019 | |
| Shire North American Group INC | $21.54 | 2019 | |
| Tris Pharma INC | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.